For the TNBC cohort, the top five favorable prognostic markers were Lymph: PD-L1 ratio, Lymph: PD-L1 proportion, Tumor: CD8 proportion, Tumor: CD8 purity, and Lymph: CD163 proportion. This evidence concerns the gene CD274 and neoplasm.